Chimeric antigen receptor (CAR) T cell therapies have shown success in treating certain blood cancers, but adapting these treatments for solid tumors has proven challenging. In this Biocompare webinar, our two experts will discuss recent developments aimed at enhancing the effectiveness of CAR T cells in solid tumor settings. They will provide insights into engineering approaches designed to enhance tumor infiltration and immune activation as well as address key barriers that have limited clinical success to date.
Denis Wirtz from Johns Hopkins University will present research on self-propelled, tumor-infiltrating CAR T cells using synthetic velocity receptors. This approach aims to enhance the migration of CAR T cells into solid tumors by introducing synthetic receptors that support cellular movement and infiltration.
John P. Murad from the Keck School of Medicine at USC will discuss immune-cytokine engineered CAR T cells, emphasizing strategies to boost the persistence and function of these cells in solid tumor microenvironments. By modifying cytokine response pathways, his team seeks to advance more durable CAR T cell activity against solid tumors.
What You Will Learn
- Methods to increase CAR T cell migration and infiltration into solid tumors via synthetic velocity receptors.
- Immune-cytokine engineering strategies to improve CAR T cell function and persistence.
- Key challenges and advances in the cellular engineering of CAR T cells for solid tumor indications.
This webinar is essential for those interested in practical aspects of CAR T cell design and the latest research on overcoming barriers in solid tumor therapy.